Generic versions of Marinol should be classified as Schedule III when they are approved, according to the Drug Enforcement Administration
Because generic versions of Marinol (dronabinol, Solvay Pharmaceuticals) are in development, DEA is proposing to put these upcoming products that contain tetrahydrocannabinols (THC), when approved, under the same classification of Schedule III. THC is believed to be the major psychoactive component of the cannabis (marijuana) plant. This DEA proposal was published in the Sept. 24
2 Commerce Drive
Cranbury, NJ 08512